VENTYX BIOSCIENCES INC (VTYX) Fundamental Analysis & Valuation

NASDAQ:VTYX • US92332V1070

Current stock price

14 USD
+0.02 (+0.14%)
At close:
13.99 USD
-0.01 (-0.07%)
After Hours:

This VTYX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VTYX Profitability Analysis

1.1 Basic Checks

  • VTYX had negative earnings in the past year.
  • VTYX had a negative operating cash flow in the past year.
  • VTYX had negative earnings in each of the past 5 years.
  • In the past 5 years VTYX always reported negative operating cash flow.
VTYX Yearly Net Income VS EBIT VS OCF VS FCFVTYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • VTYX's Return On Assets of -50.41% is on the low side compared to the rest of the industry. VTYX is outperformed by 63.73% of its industry peers.
  • VTYX has a Return On Equity of -55.71%. This is comparable to the rest of the industry: VTYX outperforms 48.19% of its industry peers.
Industry RankSector Rank
ROA -50.41%
ROE -55.71%
ROIC N/A
ROA(3y)-49.18%
ROA(5y)-2852.36%
ROE(3y)-54.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VTYX Yearly ROA, ROE, ROICVTYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5K -10K

1.3 Margins

  • VTYX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTYX Yearly Profit, Operating, Gross MarginsVTYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

8

2. VTYX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, VTYX has more shares outstanding
  • VTYX has more shares outstanding than it did 5 years ago.
  • VTYX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VTYX Yearly Shares OutstandingVTYX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
VTYX Yearly Total Debt VS Total AssetsVTYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • VTYX has an Altman-Z score of 25.06. This indicates that VTYX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of VTYX (25.06) is better than 90.16% of its industry peers.
  • VTYX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 25.06
ROIC/WACCN/A
WACCN/A
VTYX Yearly LT Debt VS Equity VS FCFVTYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 17.86 indicates that VTYX has no problem at all paying its short term obligations.
  • VTYX has a better Current ratio (17.86) than 89.12% of its industry peers.
  • A Quick Ratio of 17.86 indicates that VTYX has no problem at all paying its short term obligations.
  • VTYX has a better Quick ratio (17.86) than 89.12% of its industry peers.
Industry RankSector Rank
Current Ratio 17.86
Quick Ratio 17.86
VTYX Yearly Current Assets VS Current LiabilitesVTYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

1

3. VTYX Growth Analysis

3.1 Past

  • VTYX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.44%, which is quite impressive.
EPS 1Y (TTM)36.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • VTYX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.83% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.5%
EPS Next 2Y5.91%
EPS Next 3Y1.01%
EPS Next 5Y9.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VTYX Yearly Revenue VS EstimatesVTYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B
VTYX Yearly EPS VS EstimatesVTYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 -6

0

4. VTYX Valuation Analysis

4.1 Price/Earnings Ratio

  • VTYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTYX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTYX Price Earnings VS Forward Price EarningsVTYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTYX Per share dataVTYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.91%
EPS Next 3Y1.01%

0

5. VTYX Dividend Analysis

5.1 Amount

  • VTYX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

VTYX Fundamentals: All Metrics, Ratios and Statistics

VENTYX BIOSCIENCES INC

NASDAQ:VTYX (3/3/2026, 8:00:02 PM)

After market: 13.99 -0.01 (-0.07%)

14

+0.02 (+0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-19
Inst Owners84.42%
Inst Owner Change19.9%
Ins Owners4.22%
Ins Owner Change-21.51%
Market Cap1.00B
Revenue(TTM)N/A
Net Income(TTM)-106.61M
Analysts70.67
Price Target13.64 (-2.57%)
Short Float %7.07%
Short Ratio1.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.41%
Min EPS beat(2)20.73%
Max EPS beat(2)30.09%
EPS beat(4)4
Avg EPS beat(4)24.4%
Min EPS beat(4)20.73%
Max EPS beat(4)30.09%
EPS beat(8)8
Avg EPS beat(8)19.04%
EPS beat(12)9
Avg EPS beat(12)10.5%
EPS beat(16)12
Avg EPS beat(16)11.87%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.34%
EPS NY rev (1m)0%
EPS NY rev (3m)0.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.25
P/tB 5.25
EV/EBITDA N/A
EPS(TTM)-1.5
EYN/A
EPS(NY)-1.74
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS0
BVpS2.67
TBVpS2.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.41%
ROE -55.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.18%
ROA(5y)-2852.36%
ROE(3y)-54.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -20.8%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.86
Quick Ratio 17.86
Altman-Z 25.06
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)216.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y25.5%
EPS Next 2Y5.91%
EPS Next 3Y1.01%
EPS Next 5Y9.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.12%
EBIT Next 3Y5.59%
EBIT Next 5YN/A
FCF growth 1Y45.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.88%
OCF growth 3YN/A
OCF growth 5YN/A

VENTYX BIOSCIENCES INC / VTYX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of VENTYX BIOSCIENCES INC (VTYX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to VTYX.


What is the valuation status for VTYX stock?

ChartMill assigns a valuation rating of 0 / 10 to VENTYX BIOSCIENCES INC (VTYX). This can be considered as Overvalued.


How profitable is VENTYX BIOSCIENCES INC (VTYX) stock?

VENTYX BIOSCIENCES INC (VTYX) has a profitability rating of 0 / 10.


How financially healthy is VENTYX BIOSCIENCES INC?

The financial health rating of VENTYX BIOSCIENCES INC (VTYX) is 8 / 10.